In particular, bevacizumab, the first approved anti-angiogenic agent to bind all isoforms of VEGF-A, was approved for metastatic, HER2-negative breast cancer in 2008, based on the E2100 trial in which the progression-free survival was significantly improved [13, 33]. The gene discussed is ERBB2; the disease is breast carcinoma.